Syngene Ipo

• 

  Over 50% Listed Companies Trade Above Issue Price So Far this Year

  Some of the companies that are trading above their issue price include Navkar Corporation, Syngene International, PNC Infratech and VRL Logistics.

• 

  Market Turbulence Rattles Small IPOs as Bigger Deals Loom

  Shares hit their lowest level in about a year last week, hit by global turbulence sparked by steep market drops in China. Foreign investors - crucial in larger offerings - sold a record amount of shares in August, offloading even more than during the financial crisis.

• 

  Syngene Makes Stellar Debut, Surges 27% on Listing

  Syngene International's IPO was subscribed over 32 times last month, helping it raise an estimated Rs 550 crore. The company had also raised Rs 150 crore from anchor investors. The IPO had opened on July 27 and closed on July 29.

• Alkem Laboratories to Raise Rs 1,500-3,500 Crore via IPO: Report

  The move follows the blockbuster IPO of Syngene International, biotechnology major Biocon's research arm. With this public offer, the company is expected to be valued at around Rs 15,000 crore.

• Investors Reposed Faith in Our Future Growth Prospects: Syngene

  The company's IPO received bids for 51,27,89,640 shares as against 1,60,00,000 shares on offer, according to data available with the NSE.

• 

  Syngene IPO Subscribed 32 Times on Last Day

  In a strong show, the Rs 550-crore initial public offer (IPO) of biotechnology major Biocon's research arm, Syngene International, was over-subscribed 32.03 times on its last day on Wednesday as both retail and institutional investors bid aggressively for the shares.

• Syngene IPO Over-Subscribed on Day 2

  Syngene International's initial public offer (IPO) was over-subscribed on its second day on Tuesday.

• 

  Syngene IPO Subscribed 32% on Day 1

  The IPO received bids for 51.66 lakh shares against 1.6 crore on offer, according to NSE data till 1600 hours.

• 

  Syngene International IPO Subscribed 32% on Day 1: Read This Before Investing

  Syngene International is offering 2.2 crore shares in the price band of Rs 240-Rs 250. The issue is essentially an offer for sale wherein proceeds from the IPO will not be ploughed back in the company. Its parent Biocon is selling 11 per cent stake in the company which will bring down its stake to 74.5 per cent from 85.5 per cent now.

• Syngene to Raise Rs 150 Crore from Anchor Investors

  Syngene's initial public offer (IPO) will open on July 27.

• Biocon Surges Over 4% on Strong Q1 Earnings

  Biocon said the biopharmaceuticals segment benefitted from a strong contribution from the insulin and biosimilar business in the emerging markets.

• 

  Biocon Says May Demerge Syngene in Long Run, Post IPO

  Syngene provides contract drug discovery, research and manufacturing services to 17 of the world's top 20 pharmaceutical companies, including Bristol Myers Squibb & Co and Abbott Laboratories Ltd. Its revenue rose 25 percent in the last three years.

• 

  Biocon Sets Syngene's IPO Price Band at Rs 240-250

  Syngene's IPO shall open for subscription on July 27 and close on July 29, Biocon said in a filing to exchanges.

• 

  Biocon Rises 3% After Research Arm Gets Nod for IPO

  Shares of Biocon rose as much as 3 per cent on Tuesday after the research arm of the biotechnology major received the capital markets regulator's approval to launch an initial public offer (IPO).

• Biocon's Arm Syngene Gets Sebi Nod for IPO

  The company had filed its draft red herring prospectus (DRHP) with Sebi through its lead merchant banker Axis Capital in April.